Trius Therapeutics, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares for Common Stock Offering

Trius Therapeutics, Inc. Announces Exercise of Underwriters' Option to
Purchase Additional Shares for Common Stock Offering

SAN DIEGO, Jan. 23, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc.
(Nasdaq:TSRX) today announced that the underwriters of its previously
announced public offering of common stock that priced on January 17, 2013,
have exercised their option to purchase an additional 869,135 shares of common
stock. With the sale of the additional shares, Trius will have sold a total of
7,169,135 shares of common stock in the public offering at a price to the
public of $4.75 per share, resulting in expected aggregate gross proceeds to
Trius of approximately $34.1 million, before deducting underwriting discounts
and commissions and other estimated offering expenses payable by Trius. The
offering, including the sale of the additional shares, is expected to close on
or about January 24, 2013, subject to customary closing conditions.

Trius anticipates using the net proceeds from the offering for general
corporate purposes, including clinical trial, preclinical and other research
and development expenses, capital expenditures, working capital and general
and administrative expenses.

Citigroup and Leerink Swann acted as joint book-running managers and Baird
acted as a co-lead manager in the offering.

The securities described above were offered by Trius pursuant to two shelf
registration statements previously filed with and declared effective by the
Securities and Exchange Commission (the "SEC")onSeptember 15, 2011 and
September 11, 2012. Prospectus supplements related to the offering have been
filed with theSECand are available on the SEC's website at Copies of the prospectus supplements and accompanying
prospectuses relating to these securities may also be obtained from Citigroup,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY
11717, via telephone at 1-800-831-9146 or email at
or from Leerink Swann LLC, Attention: Syndicate Department, One Federal
Street, 37^th Floor, Boston, MA 02110, via telephone at 1-800-808-7525 or
email at This press release shall not constitute an
offer to sell or the solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such state or
other jurisdiction.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the
discovery and development of innovative antibiotics for serious infections.
The company's lead investigational drug, tedizolid phosphate, is a once daily,
IV and orally administered second generation oxazolidinone in Phase 3 clinical
development for the treatment of serious gram-positive infections, including
those caused by methicillin-resistant Staphylococcus aureus (MRSA). Trius has
partnered with Bayer HealthCare for the development and commercialization of
tedizolid phosphate outside of the U.S., Canada and the European Union. In
addition to the company's tedizolid phosphate clinical program, Trius has
initiated Investigational New Drug enabling studies for its Gyrase-B
development candidate with potent activity against Gram-negative bacterial
pathogens including multi-drug resistant strains of E. coli, Klebsiella,
Acinetobacter and Pseudomonas.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such statements are
subject to risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such statements
include, but are not limited to, Trius' expectations regarding the closing of
the public offering and the expected gross proceeds therefrom. Among the
factors that could cause actual results to differ materially from those
indicated in the forward-looking statements are risks and uncertainties
associated with market conditions and the satisfaction of customary closing
conditions related to the offering, as well as risks and uncertainties
associated with Trius' business and finances in general, and the other risks
described in Trius' Quarterly Report on Form 10-Q for the quarter ended
September 30, 2012, and in the prospectus supplements related to the offering
filed with the SEC. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Trius undertakes no
obligation to update such statements to reflect events that occur or
circumstances that exist after the date on which they were made.

CONTACT: Public Relations Contact:
         Laura Kempke/Andrew Law at MSLGROUP
         Investor Relations Contact:
         Stefan Loren at Westwicke Partners, LLC
Press spacebar to pause and continue. Press esc to stop.